Edwards Lifesciences raises FY26 guidance following strong Q1

Edwards Lifesciences has lifted its full-year 2026 maturation outlook to betwixt 9% and 11%, up from 8% to 10% previously, owed to ‘better than expected’ show successful Q1.

The medtech elephantine reported revenues of astir $1.65bn successful Q1, driven by dependable double-digit maturation crossed its portfolio. With the percent uplift for the afloat year, Edwards present anticipates income of $6.5bn to $6.9bn, with net mooted to autumn successful the $2.95 to $3.05 per stock range, up from $2.90 to $3.05 previously.

Edwards released its Q1 results aft the marketplace closed connected 23 April. The company’s shares connected the New York Stock Exchange (NYSE), close arsenic astatine 12pm BST connected 24 April, were up by implicit 2% astatine $81.51, versus $79.72 astatine marketplace adjacent connected the anterior day.

Edwards transcatheter aortic valve replacement (TAVR) concern pulled successful the bulk of the quarter’s income astatine astir $1.2bn, representing a year-over-year (YoY) maturation complaint of 14.4%.

GlobalData investigation reveals that the TAVR marketplace is projected to scope a valuation of $14.9bn successful 2034, up from $6.8bn successful 2024. Further information from GlobalData indicates that Edwards presently holds $4.53bn successful gross successful the TAVR space, with a US marketplace stock of implicit 60%.

Elsewhere crossed the business, Edwards reported 10.1% maturation successful its surgical portfolio to $276.2m. Meanwhile, though Edwards’ transcatheter mitral and tricuspid therapies conception was the smallest gross driver, pulling successful $175.1m, it saw the astir important maturation astatine 59.9% YoY.

Bernard Zovighian, Edwards’ CEO, commented: “Building connected a twelvemonth successful 2025 marked by coagulated fiscal show and strategical progress, we delivered different beardown 4th successful Q1, achieving 12.7% income growth, which reflects the interaction and durability of our focused strategy. We stay dedicated to solving large, urgent and analyzable diligent needs and pursuing unsocial opportunities to innovate and pb successful structural bosom disease.”

Medtech rival Boston Scientific besides released its Q1 financials this week. While the institution reported dependable Q1 performance, dissimilar Edwards, it chose to temper its anterior full-year maturation outlook, citing “ongoing competitory dynamics”.

"Edwards Lifesciences raises FY26 guidance pursuing beardown Q1" was primitively created and published by Medical Device Network, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.